Mather Group’s ResMed RMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$141K Sell
636
-8
-1% -$1.74K ﹤0.01% 875
2026
Q2
$126K Sell
644
-70
-10% -$14.5K ﹤0.01% 886
2026
Q1
$160K Buy
+714
New +$178K ﹤0.01% 783
2025
Q4
– Sell
-705
Closed -$193K – 1435
2025
Q3
$193K Buy
+705
New +$193K ﹤0.01% 627
2025
Q2
– Sell
-692
Closed -$155K – 1478
2025
Q1
$155K Sell
692
-15
-2% -$3.5K ﹤0.01% 658
2024
Q4
$162K Buy
707
+6
+0.9% +$1.44K ﹤0.01% 629
2024
Q3
$171K Buy
701
+74
+12% +$16.5K ﹤0.01% 619
2024
Q2
$124K Buy
627
+24
+4% +$4.87K ﹤0.01% 748
2024
Q1
$104K Buy
+603
New +$110K ﹤0.01% 695
2023
Q3
– Sell
-1,425
Closed -$311K – 610
2023
Q2
$311K Buy
1,425
+328
+30% +$73.1K 0.01% 452
2023
Q1
$240K Sell
1,097
-165
-13% -$35.8K ﹤0.01% 448
2022
Q4
$263K Sell
1,262
-291
-19% -$63.9K 0.01% 409
2022
Q3
$339K Sell
1,553
-65
-4% -$14.8K 0.01% 346
2022
Q2
$339K Buy
+1,618
New +$344K 0.01% 288

Other funds holding RMD

Mather Group's RMD Position: Q3 2026 in Review

Mather Group reduced its ResMed (RMD) stake by 1.2% in Q3 2026, selling an estimated $1.74K and leaving 636 shares worth $141K. The position accounts for ﹤0.01% of the portfolio, ranked #875.

Mather Group first reported a position in RMD in Q2 2022 and has held it in 14 quarters since. The position peaked at $339K in Q3 2022. 167 funds tracked by Wall St. Rank hold RMD as of Q3 2026.

  • Mather Group held 636 shares of ResMed worth $141K as of Q3 2026.
  • Mather Group sold 8 ResMed shares in Q3 2026, an estimated $1.74K.
  • ResMed made up ﹤0.01% of Mather Group's portfolio in Q3 2026, its #875 holding.
  • Mather Group first reported a position in ResMed in Q2 2022 and has held it in 14 quarters since.
  • Mather Group's ResMed position peaked at $339K in Q3 2022.
  • 167 funds tracked by Wall St. Rank held ResMed as of Q3 2026.

Based on Mather Group's 13F filing for Q3 2026, filed 14 Oct 2026.